AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06680466
Drug: YZJ-4729
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Group 2
Trial: NCT06680466
Drug: YZJ-4729
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Group 3
Trial: NCT04775082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
Trial: NCT05615623
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin infusion
Trial: NCT06680466
Drug: YZJ-4729
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Group 4
Trial: NCT06206876
Drug: DDX5 Degrader FL118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06681038
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.
Trial: NCT04588428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
Trial: NCT06251310
Drug: SW-682
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SW-682 tablet administered orally
Trial: NCT06717880
Drug: IBI363 + Furuitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 Q2W or Q3W IV，Furuitinib po
Trial: NCT06066125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
Trial: NCT04974138
Drug: Amlodipine besylate and folic acid
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Trial: NCT04974138
Drug: Amlodipine-folic acid placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
Trial: NCT05473273
Drug: Endometrin 100Mg Vaginal Insert
RxNorm normalized name: Endometrin 100mg Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
Trial: NCT04850495
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04850495
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04677816
Drug: Standard of Care Neoadjuvant Chemotherapy (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
Trial: NCT06680609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
Trial: NCT06393712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intrathecally
Trial: NCT06393712
Drug: ALN-APP
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ALN-APP will be administered intrathecally
Trial: NCT06058702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
Trial: NCT05253651
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
Trial: NCT05253651
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Trial: NCT06277934
Drug: RGT001-075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06277934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05200403
Drug: Vehicle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
Trial: NCT06708481
Drug: P11-4, a self-assembling peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
Trial: NCT06708481
Drug: P11-4, a self-assembling peptide with flouride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self assembling peptide with 500 ppm sodium fluoride
Trial: NCT06710704
Drug: Methylprednisolone and mepacaine
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
Trial: NCT06315335
Drug: UCB9741
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
Trial: NCT06315335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
Trial: NCT04669821
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
Trial: NCT05615415
Drug: PET Tracer
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
Trial: NCT05615415
Drug: MRI Tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected via intravenous catheter during PET-MR scanning.
Trial: NCT06710665
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT06707480
Drug: Taurolidine and Heparin
RxNorm normalized name: heparin / taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter Lock Solution
Trial: NCT05073458
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered QD orally follwed by Parsaclisinib in the open label period
Trial: NCT05971485
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
Trial: NCT05480878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT04704843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
Trial: NCT05912517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an intravenous infusion.
Trial: NCT06315231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive one placebo twice daily for 24 weeks
Trial: NCT04251182
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily in the morning
Trial: NCT05605899
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05605899
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT06261671
Drug: antioxidants-enriched culture medium (Gx)
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
Trial: NCT04455750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06207877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT05917509
Drug: DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/3TC FDC will be administered as an oral once daily tablet.
Trial: NCT06393101
Drug: BRC-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
Trial: NCT06393101
Drug: BRC-002 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of mono-, di-, and triglycerides
Trial: NCT06205485
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2
Trial: NCT06205485
Drug: Fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
Trial: NCT06205485
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m2 twice daily for 14 days
Trial: NCT05546411
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
Trial: NCT05546411
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT06014905
Drug: Hyperpolarized carbon C 13 pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Intravenously (IV)
Trial: NCT04501614
Drug: Chemotherapy Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
Trial: NCT05009069
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
Trial: NCT05009069
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
Trial: NCT06173934
Drug: insulin injection 15 minutes before meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjust insulin injection time to observe blood glucose spectrum
Trial: NCT06173934
Drug: Insulin injection 15 minutes after eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjust insulin injection time to observe blood glucose spectrum
Trial: NCT05482542
Drug: Cyclophosphamide/ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide/ATG
Trial: NCT03593317
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
Trial: NCT03593317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
Trial: NCT06572813
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
Trial: NCT04889183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
Trial: NCT05602142
Drug: [11C]CPPC PET ligand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
Trial: NCT06219317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard saline solution
Trial: NCT03459729
Drug: Antitumor B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
Trial: NCT06133972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. monthly
Trial: NCT06223074
Drug: Nasal Methylprednisolone (MT)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
Trial: NCT05132504
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
Trial: NCT05844137
Drug: T2D medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T2D medication management
Trial: NCT04231760
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Trial: NCT04231760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Trial: NCT06611319
Drug: Prevention of Venous Thromboembolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulant
Trial: NCT06611319
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06745297
Drug: Placebo matching BI 3776528
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 3776528
Trial: NCT05511246
Drug: Venous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
Trial: NCT05928728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT05806086
Drug: Panfoshu+Conventional Treatment（program-A）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
Trial: NCT05806086
Drug: Panfoshu+Conventional Treatment（program-B）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
Trial: NCT06525597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05693766
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg taken by mouth twice daily for 7 days on, 7 days off
Trial: NCT06012760
Drug: Standard Medical Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
Trial: NCT04954456
Drug: QLS31901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
Trial: NCT05643638
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
Trial: NCT06483373
Drug: SPH7854
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH7854： Orally, 50-3200mg
Trial: NCT06483373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo：Orally；
Trial: NCT06534437
Drug: MEN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN1703 is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Trial: NCT05905328
Drug: CTO1681 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times daily for 15 days (initial cohort).
Trial: NCT05905328
Drug: CTO1681 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times daily for 15 days (successive cohort).
Trial: NCT05905328
Drug: CTO1681 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times daily for 15 days (successive cohort).
Trial: NCT06484556
Drug: NW-301V
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12V mutation
Trial: NCT06484556
Drug: NW-301D
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12D mutation